VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.
about
Microbial translocation in chronic liver diseasesRole of NLRP3 Inflammasome in the Progression of NAFLD to NASHGut Microbiota and Lifestyle Interventions in NAFLDDiet, Microbiota, Obesity, and NAFLD: A Dangerous QuartetInvolvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesityDietary habits and behaviors associated with nonalcoholic fatty liver diseaseLeaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitisGut microbiota and liver diseasesDifference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in miceRandomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis.Toll-like receptor 4 and hepatic fibrogenesisVSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.Review article: the management of paediatric nonalcoholic fatty liver disease.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease in children: focus on nutritional interventions.Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient dietThe Gordian Knot of dysbiosis, obesity and NAFLD.The gut microbiota and the liver: implications for clinical practice.Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.Potent natural products and herbal medicines for treating liver fibrosisBifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis.Gut microbiota and diabetes: from pathogenesis to therapeutic perspective.MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targetsLactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice.Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial.Activation of Kupffer Cells Is Associated with a Specific Dysbiosis Induced by Fructose or High Fat Diet in MiceToll-like receptors in liver fibrosis: cellular crosstalk and mechanismsPrecision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.Advances in the treatment of nonalcoholic fatty liver disease.Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice.The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical TrialThe Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease.Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activationGreen tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet.
P2860
Q21284997-AF344F2B-7077-4309-B8A0-EF4D7C166301Q26742102-1BB3B62B-9A0C-448A-90B4-07EB92205F26Q26749783-9532AD5B-C2CE-40E3-9186-15272787C4EEQ26752614-73E95E47-1314-47CB-B12E-D497BB7FF7AEQ26828547-E341674B-3FB6-497F-A4A5-D4286D7139A9Q26830594-EA166A44-E913-4E1D-A129-A90F90ACACAAQ26991664-C9F5AFAA-16D6-4BE1-A7AF-F9A8BD9AC51FQ27015127-69DCF367-63C5-4813-844E-2F93FFA77ABBQ28507402-3BABA8E5-B94D-4AA4-8A9B-CE201F8D5E35Q33714116-11FAD9DF-8620-4A0E-93A0-1867368D2A7AQ33755829-2E1974F3-4A01-4ECC-99E6-465B68EC2EACQ33817253-7786BAE1-CA87-45C6-BA89-F21C4A38E215Q33905721-0EB30891-EC10-43B2-A8FB-236D7A39FEAAQ34428997-ED9D8389-0D02-4138-B6DE-F09CEE076E8CQ34440962-D1E5EDCC-9503-4EB6-93CB-9C2A0EC3779DQ34499017-F9977222-4618-4A03-B50F-2DCF02A69BBCQ34577949-4C74D840-DD6B-4F0D-AACF-1C3BF9A60209Q34589677-887CD0C9-1F94-4750-ABC0-B9695FD27191Q34641213-E3797DC9-A5F7-429A-9A72-8502F9570103Q34733841-929EA7AE-2833-4A45-BC1D-ECB7A0BE4A34Q34854719-52801456-EC34-4A88-8C36-32A84114F22CQ34956813-39C298B7-8ACF-4B8E-AE0D-43C3ED102E01Q35019661-6DED56B4-3505-4089-B4E6-20EDC6A6FDDCQ35127037-E6F92F7D-8A3E-419F-A7FB-A7345A4785EEQ35494410-9987BA4B-8CC4-4468-9AFE-73A30DB855A4Q35556323-6D9AD009-1A13-4B5A-B8AF-069A0A51D9F0Q35573510-7C08C6AE-43BF-4F74-B1C7-788DE9B1D1F0Q35652509-2C7EF8C1-52A5-4E49-BA71-05BC25E9278FQ35668745-C8643FD3-6B85-44B3-BFA5-8260BF09E963Q35679003-DDB82A94-A6A8-4347-AB5B-9E762E1A29FCQ35865699-1498A07B-8529-44D4-9C83-2DAE59618FF1Q35885676-D75FD6DF-7108-41E8-82B5-7372F0EF42EDQ35977675-111731E9-ADEC-44BA-8F2A-8A9154BB9CFCQ36148926-6B466AF0-6916-473C-BCD8-BE8DD6F896EAQ36329908-E72E16F0-160F-4D1D-89F8-E5887BECE7D4Q36513460-B08CF05B-4D69-4B63-B7C5-F5CE17ED2ED2Q36732958-B5ACBB17-993F-4185-99EF-00C3291D06A3Q36751990-235A3CC2-8910-4A81-BFAE-9BC0145AEA3DQ36775835-DC8722C1-0AB2-4374-AF0C-E438A73E3939Q36788693-4276C466-B6E9-469A-BE98-2F5453F726C6
P2860
VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@en
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@nl
type
label
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@en
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@nl
prefLabel
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@en
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice.
@nl
P2093
P2860
P356
P1433
P1476
VSL#3 probiotic treatment atte ...... steatohepatitis model in mice
@en
P2093
Angela Dolganiuc
Arumugam Velayudham
Gyongyi Szabo
Jan Petrasek
Karen Kodys
Michael Ellis
P2860
P304
P356
10.1002/HEP.22711
P407
P577
2009-03-01T00:00:00Z